157 results
Page 4 of 8
8-K
EX-99.1
gcp3d
30 Jul 20
Agios Reports Business Highlights and Second Quarter 2020 Financial Results
7:17am
8-K
EX-99.2
cs8wf6y4l7
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
8-K
EX-99.3
9g1z epzuuhmyiu
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
8-K
EX-99.1
p7n2dk
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
S-3ASR
wjl99xn7f4
30 Apr 20
Automatic shelf registration
4:19pm
8-K
EX-99.1
23l0s2a omb9
30 Apr 20
Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations andCOVID-19 Response
7:19am
8-K
EX-99.1
feo6uhzdbqvrq
13 Feb 20
Agios Reports Fourth Quarter and Full Year 2019 Financial Results
7:40am
8-K
EX-99.1
zo61cfx
13 Jan 20
Agios Announces “Agios 2025” Strategic Vision and Highlights 2020 Milestones
6:43am
8-K
EX-99.1
jcwwmg3vp
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.3
cj3zzrv o8
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.2
w1xqs4xo4qrwtfjcp
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.1
lgyxet18g
22 Nov 19
Other Events
5:01pm
424B5
u8zxx6
8 Nov 19
Prospectus supplement for primary offering
5:03pm
8-K
EX-99.1
fe42yi25n9f9rv
8 Nov 19
Agios Announces Pricing of $256 Million Public Offering of Common Stock
4:57pm
424B5
m6ysbu
6 Nov 19
Prospectus supplement for primary offering
4:07pm